Abstract
The recent pandemic caused by a novel coronavirus known as SARS-CoV-2 has caught the international community by surprise. There is still no effective vaccine or treatment option against this virus. In this perspective, we discussed the potential protective and therapeutic effects of chitosan, as an FDA-approved biomolecule, against COVID-19 and influenza viruses.
Keywords: Chitosan, COVID-19, immune response, innate Immunity, biotherapeutic, macromolecule.
[http://dx.doi.org/10.1016/j.virusres.2020.198114] [PMID: 32800805]
[http://dx.doi.org/10.1016/S0140-6736(20)31605-6] [PMID: 32702299]
[http://dx.doi.org/10.1002/jmv.26014] [PMID: 32410338]
[http://dx.doi.org/10.1016/S0140-6736(20)31052-7] [PMID: 32423586]
[http://dx.doi.org/10.3389/fmicb.2020.00372] [PMID: 32256465]
[http://dx.doi.org/10.1016/j.autrev.2017.05.012] [PMID: 28483543]
[http://dx.doi.org/10.4103/0973-7847.176545] [PMID: 27041872]
[http://dx.doi.org/10.1016/0142-9612(94)90272-0] [PMID: 7703317]
[http://dx.doi.org/10.1016/S0141-3910(97)00160-2]
[http://dx.doi.org/10.1079/BJN19940029] [PMID: 7947645]
[http://dx.doi.org/10.1016/j.eurpolymj.2012.12.009]
[http://dx.doi.org/10.1016/j.cis.2018.11.008] [PMID: 30530176]
[http://dx.doi.org/10.1080/08905439109549790]
[http://dx.doi.org/10.1080/09593332808618893] [PMID: 18341146]
[http://dx.doi.org/10.1016/j.biomaterials.2018.08.054] [PMID: 30195140]
[http://dx.doi.org/10.1007/s11356-014-3571-7] [PMID: 25226839]
[http://dx.doi.org/10.1016/j.immuni.2016.02.004] [PMID: 26944200]
[http://dx.doi.org/10.1016/j.carbpol.2019.115423] [PMID: 31826462]
[http://dx.doi.org/10.1016/j.ijbiomac.2020.02.287] [PMID: 32114177]
[http://dx.doi.org/10.1016/j.genrep.2020.100708]
[http://dx.doi.org/10.1128/IAI.65.5.1734-1741.1997] [PMID: 9125555]
[http://dx.doi.org/10.1038/srep28729] [PMID: 27353250]
[http://dx.doi.org/10.3390/md9061038] [PMID: 21747747]
[http://dx.doi.org/10.1038/ni873] [PMID: 12469119]
[http://dx.doi.org/10.1016/j.antiviral.2016.03.008] [PMID: 26971407]
[http://dx.doi.org/10.4110/in.2018.18.e33] [PMID: 30402328]
[http://dx.doi.org/10.1016/j.immuni.2016.05.006] [PMID: 27287409]
[http://dx.doi.org/10.1016/j.ajpath.2011.09.003] [PMID: 22001698]
[PMID: 21296109]
[http://dx.doi.org/10.3389/fmicb.2019.01057] [PMID: 31134045]
[http://dx.doi.org/10.4049/jimmunol.174.3.1549] [PMID: 15661915]
[http://dx.doi.org/10.3109/10837459709031444] [PMID: 9552452]
[http://dx.doi.org/10.1016/0378-5173(92)90353-4]
[http://dx.doi.org/10.1016/S0378-5173(97)00287-1]
[http://dx.doi.org/10.1023/A:1016444808000] [PMID: 8956335]
[http://dx.doi.org/10.1093/toxsci/kfr198] [PMID: 21821733]
[http://dx.doi.org/10.1038/oby.2003.97] [PMID: 12740459]
[http://dx.doi.org/10.1080/07315724.2008.10719671] [PMID: 18460478]
[PMID: 11838268]
[http://dx.doi.org/10.3390/pharmaceutics9040053] [PMID: 29156634]